Adial Pharmaceuticals Inc

ADIL·NasdaqCM·Healthcare
Compare
5.05+1.34 (+36.12%)today
At close: Oct 28, 3:00 PM EST · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close3.71
Open3.83
Day range3.825.15
52-week range1.318.75
Off day high−1.94%
Off 52-week high−42.29%
Volume83.09K
Avg. volume (3M)56.77K
Market cap13.26M
EPS (TTM)-20.65
Forward P/E-0.68
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)1.50
Shares outstanding2.63M
Short interest6.87% of float
Earnings dateAug 11, 2025 (est.)
Analyst target8.33
Profit margin0.00%

Against its peers

Compare in full ›
ADIL ACET EOCN TCRT ADXN CANF
Market cap 13.26M 29.02M 2.96M 6.19M 5.33M 5.06M
P/E (TTM) — — — — — —
Forward P/E -0.7 -0.8 — -3.0 -60.9 -1.8
Price/book -0.3 0.3 0.2 6.9 1.4 0.7
Dividend yield — — — — — —
1-year change −50.74% −71.38% −71.44% −26.83% −65.70% −80.71%
Today +36.12% −2.21% −1.42% −3.23% +1.27% +3.02%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All ADIL news ›
Seeking Alpha·Positive

Adial Pharmaceuticals to appoint Celia Economides as CFO

Adial Pharmaceuticals plans to appoint Celia Economides as CFO after its 2026 annual meeting. Adial Pharmaceuticals (ADIL) announced Monday that Celia Economides, the company’s current executive vice president of finance, is expected to be…

Stock Titan·

Adial Pharmaceuticals delays votes to October 26

Stockholders who already submitted votes on Proposals 3–6 need take no further action unless they wish to change them. Adial Pharmaceuticals, Inc. further adjourned its 2026 Annual Meeting vote on Proposals 3, 4, 5 and 6 because it had not…

Quiver Quantitative··2 outletsPositive

Adial Pharmaceuticals Appoints AhR Drug Development Veteran David Rubenstein as Chief Scientist to Advance AT177 for Ulcerative Colitis

Adial Pharmaceuticals appoints David Rubenstein as Chief Scientist to lead development of AT177 for ulcerative colitis. David Rubenstein, M.D., Ph.D. is the Chief Scientist at Adial Pharmaceuticals, overseeing research and scientific…

More from 1 other outlet

From the 4Search news index, newest first.

In the news

5mentions in 30 days
5with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance